DEXCOM, INC. DexCom, Inc. Stock BOERSE MUENCHEN
Equities
DC4
US2521311074
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 107.6 EUR | -2.04% |
|
-8.39% | -4.05% |
| 05-30 | Redburn Atlantic Initiates DexCom With Neutral Rating, $130 Price Target | MT |
| 05-24 | Declaration of Voting Results by DexCom, Inc | CI |
| Sales 2024 * | 4.33B 3.99B 5.9B | Sales 2025 * | 5.15B 4.75B 7.02B | Capitalization | 47.23B 43.55B 64.36B |
|---|---|---|---|---|---|
| Net income 2024 * | 732M 675M 997M | Net income 2025 * | 910M 839M 1.24B | EV / Sales 2024 * | 11.2 x |
| Net Debt 2024 * | 1.43B 1.32B 1.95B | Net Debt 2025 * | 994M 917M 1.35B | EV / Sales 2025 * | 9.36 x |
| P/E ratio 2024 * |
65.7
x | P/E ratio 2025 * |
53.7
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on DexCom, Inc.
More recommendations
More press releases
More news
| 1 week | -8.39% | ||
| Current month | -10.52% | ||
| 1 month | -10.52% | ||
| 3 months | +1.26% | ||
| 6 months | +1.09% | ||
| Current year | -4.05% |
1 week
107.50
118.64
1 month
107.50121.98
3 years
64.38144.80
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Sayer
CEO | Chief Executive Officer | 66 | 07-10-31 |
Jereme Sylvain
DFI | Director of Finance/CFO | 44 | 18-08-31 |
| Chief Tech/Sci/R&D Officer | 47 | 22-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nick Augustinos
BRD | Director/Board Member | 65 | 09-11-19 |
Mark Foletta
BRD | Director/Board Member | 63 | 14-11-18 |
Eric Topol
BRD | Director/Board Member | 69 | 09-07-08 |
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 107.6 | -2.04% |
| 24-05-30 | 109.9 | -7.01% |
| 24-05-29 | 118.2 | +0.56% |
| 24-05-28 | 117.5 | +0.29% |
| 24-05-27 | 117.2 | -0.29% |
Real-time BOERSE MUENCHEN, May 31, 2024 at 03:43 pm
More quotes
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals.
The United States accounts for 72.5% of net sales.
Calendar
2024-06-05
- William Blair Growth Stock Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
150.3
USD
Spread / Average Target
+26.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.16% | 178B | |
| -1.23% | 107B | |
| -4.86% | 67.04B | |
| +10.32% | 44.62B | |
| +8.14% | 42.5B | |
| +15.76% | 29.99B | |
| +15.53% | 25.22B | |
| -5.88% | 24.14B | |
| -5.38% | 23.69B |
- Stock Market
- Equities
- DXCM Stock
- DC4 Stock
